ATE397442T1 - Magensaftresistent beschichtetes pellet mit ixabepilon - Google Patents

Magensaftresistent beschichtetes pellet mit ixabepilon

Info

Publication number
ATE397442T1
ATE397442T1 AT05824194T AT05824194T ATE397442T1 AT E397442 T1 ATE397442 T1 AT E397442T1 AT 05824194 T AT05824194 T AT 05824194T AT 05824194 T AT05824194 T AT 05824194T AT E397442 T1 ATE397442 T1 AT E397442T1
Authority
AT
Austria
Prior art keywords
ixabepilone
resistant coated
coated pellet
juice resistant
enteric juice
Prior art date
Application number
AT05824194T
Other languages
German (de)
English (en)
Inventor
Ismat Ullah
Gary WILEY
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE397442T1 publication Critical patent/ATE397442T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT05824194T 2004-11-18 2005-11-17 Magensaftresistent beschichtetes pellet mit ixabepilon ATE397442T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62897004P 2004-11-18 2004-11-18

Publications (1)

Publication Number Publication Date
ATE397442T1 true ATE397442T1 (de) 2008-06-15

Family

ID=35976527

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05824194T ATE397442T1 (de) 2004-11-18 2005-11-17 Magensaftresistent beschichtetes pellet mit ixabepilon

Country Status (25)

Country Link
US (1) US20060153917A1 (cg-RX-API-DMAC7.html)
EP (2) EP1958625A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008520696A (cg-RX-API-DMAC7.html)
KR (1) KR20070084325A (cg-RX-API-DMAC7.html)
CN (1) CN101083978A (cg-RX-API-DMAC7.html)
AR (1) AR052142A1 (cg-RX-API-DMAC7.html)
AT (1) ATE397442T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005306464A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518286A2 (cg-RX-API-DMAC7.html)
CA (1) CA2588400A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005007376D1 (cg-RX-API-DMAC7.html)
DK (1) DK1817013T3 (cg-RX-API-DMAC7.html)
ES (1) ES2306278T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20080349T3 (cg-RX-API-DMAC7.html)
IL (1) IL183116A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007005763A (cg-RX-API-DMAC7.html)
NO (1) NO20072388L (cg-RX-API-DMAC7.html)
PE (1) PE20061058A1 (cg-RX-API-DMAC7.html)
PL (1) PL1817013T3 (cg-RX-API-DMAC7.html)
PT (1) PT1817013E (cg-RX-API-DMAC7.html)
RU (1) RU2349319C1 (cg-RX-API-DMAC7.html)
SI (1) SI1817013T1 (cg-RX-API-DMAC7.html)
TW (1) TW200631609A (cg-RX-API-DMAC7.html)
WO (1) WO2006055740A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200703955B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101091725A (zh) 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
PT2835053T (pt) 2010-03-12 2016-07-14 Genzyme Corp Terapêutica combinada para o tratamento do cancro da mama
WO2012047802A2 (en) * 2010-10-01 2012-04-12 The Johns Hopkins University Systems and methods for high-throughput microfluidic bead production
CA2826889C (en) 2011-02-11 2016-12-20 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CA2881992C (en) 2013-04-23 2016-11-22 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6288237B1 (en) * 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
JP4090529B2 (ja) * 1996-01-24 2008-05-28 フロイント産業株式会社 乳糖の球形粒及びその製造方法
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
AU720135B2 (en) * 1996-10-02 2000-05-25 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
KR100538095B1 (ko) * 1996-11-18 2005-12-21 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) 에포틸론 씨, 디, 이 및 에프, 그 제조방법 및 세포증식 억제제와 식물 위생제로서의 이들의 용도
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
CZ298027B6 (cs) * 1997-02-25 2007-05-30 Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
PT1117382E (pt) * 1998-10-01 2005-08-31 Powderject Res Ltd Microparticulas revestidas por pulverizacao para utilizacao em seringas sem agulha
NZ513268A (en) * 1999-02-18 2004-05-28 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
HK1038923B (en) * 1999-02-22 2004-03-19 Helmholtz-Zentrum Fur Infektionsforschung Gmbh C-21 modified EPOTHILONES
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
MXPA02003596A (es) * 2000-08-09 2003-10-14 Panacea Biotec Ltd Composiciones farmaceuticas novedosas de farmacos anti tubercular y procedimiento para su preparacion.
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL154986A0 (en) * 2000-09-22 2003-10-31 Biotechnolog Forschung Gmbh Triazolo-epothilone derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DE50008242D1 (de) 2000-09-26 2004-11-18 Enthone Omi Deutschland Gmbh Verfahren zur selektiven Metallisierung dielektrischer Materialien
KR100851719B1 (ko) * 2001-01-25 2008-08-11 브리스톨-마이어스스퀴브컴파니 암 치료용 에포틸론 유사체의 투여 방법
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
JP2004521122A (ja) * 2001-01-25 2004-07-15 ブリストル−マイヤーズ スクイブ カンパニー エポチロン類似体の非経口製剤
IL156988A0 (en) * 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
EP1368030A1 (en) * 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
SK11082003A3 (sk) * 2001-03-14 2004-08-03 Bristol-Myers Squibb Company Kombinácia analógov epotilónu a chemoterapeutických činidiel na liečenie proliferatívnych ochorení
MXPA03010909A (es) * 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
JP4645789B2 (ja) * 2001-06-18 2011-03-09 Jsr株式会社 ネガ型感放射線性樹脂組成物
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
ATE452896T1 (de) * 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003256157A1 (en) * 2002-08-05 2004-02-23 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
AU2003279911A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Therapeutic formulations
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof

Also Published As

Publication number Publication date
HK1106713A1 (en) 2008-03-20
KR20070084325A (ko) 2007-08-24
PL1817013T3 (pl) 2009-01-30
PE20061058A1 (es) 2006-10-13
ES2306278T3 (es) 2008-11-01
AU2005306464A1 (en) 2006-05-26
WO2006055740A1 (en) 2006-05-26
EP1817013B1 (en) 2008-06-04
MX2007005763A (es) 2007-07-20
IL183116A0 (en) 2007-09-20
PT1817013E (pt) 2008-08-07
DK1817013T3 (da) 2008-10-13
EP1958625A1 (en) 2008-08-20
NO20072388L (no) 2007-06-14
RU2349319C1 (ru) 2009-03-20
TW200631609A (en) 2006-09-16
EP1817013A1 (en) 2007-08-15
HRP20080349T3 (hr) 2009-01-31
AR052142A1 (es) 2007-03-07
DE602005007376D1 (de) 2008-07-17
CN101083978A (zh) 2007-12-05
BRPI0518286A2 (pt) 2008-11-11
SI1817013T1 (sl) 2008-12-31
US20060153917A1 (en) 2006-07-13
CA2588400A1 (en) 2006-05-26
JP2008520696A (ja) 2008-06-19
ZA200703955B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
ATE347837T1 (de) Kapsel mit dichtungsmitteln
ATE501064T1 (de) Kapsel mit reduziertem nachtropfen
EP2040682A4 (en) IMPROVED ENVELOPE MICROCAPSULES
DE602006007068D1 (de) Led mit leuchtstoff
DE602005022921D1 (de) Verschluss mit mehreren deckeln
DE602005017808D1 (de) Turbolader mit druckring
NL1028927A1 (nl) Nieuwe verbindingen.
EP1723399A4 (en) QUANTUM WELL INFRARED PHOTODETECTOR WITH TUNABLE SPECTRAL RESPONSE
DK1586922T3 (da) Böjningsbegrænser
EP1726045A4 (en) QUANTUM WELL INFRARED PHOTODETECTOR WITH ENHANCED OPTICAL COUPLING
EP1937057A4 (en) CULTIVAR OF RICE CALLED "CL131"
EP1727903A4 (en) IMPROVED EXPRESSION SHOWED MODIFIED XYLANASES
DE602004016282D1 (de) Uhrwerk mit mehreren Federhäusern
ATE454440T1 (de) Bleichmittel mit carbohydratoxidase
ATE397442T1 (de) Magensaftresistent beschichtetes pellet mit ixabepilon
DE502006007719D1 (de) Rektoskop mit lichtabstrahlenden Elementen
FI20045190L (fi) Energiantuotantojärjestely
DE602005003074D1 (de) Fluorocopolymer
DE502005008744D1 (de) Seilstraffer mit zweifachem seileinlauf
EP1803762A4 (en) HEAT-RESISTANT RESIN
DE602005004398D1 (de) Hren
ATE370218T1 (de) Tabletten mit verbessertem bruchswiderstand
ATE371716T1 (de) Tabletten mit verbessertem bruchswiderstand
NO20052538D0 (no) Lofteanker.
DE502005011107D1 (de) Förderzeug mit Anbaugerät

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1817013

Country of ref document: EP

REN Ceased due to non-payment of the annual fee